Asset
VADADUSTAT
Akebia Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (31)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02260193 | phase2 | completed | 2014-09-10 | 2015-07-22 | Akebia Therapeutics | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis |
| NCT01906489 | phase2 | completed | 2013-07-23 | 2014-09-03 | Akebia Therapeutics | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT01381094 | phase2 | completed | 2011-06-15 | 2012-02-16 | Akebia Therapeutics | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT03799848 | phase1 | completed | 2018-06-12 | 2018-10-18 | Akebia Therapeutics | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function |
| NCT03657290 | phase1 | completed | 2018-08-03 | 2018-10-16 | Akebia Therapeutics | A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 215192 | NDA | AKEBIA THERAPEUTICS INC |
Marketed products (3)
- VAFSEO
- VAFSEO
- VAFSEO